Eaton Vance Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $108M | Buy |
2,177,852
+1,618,156
| +289% | +$86.7M | 0.16% | 139 |
|
|
2022
Q2 | $31.2M | Sell |
559,696
-17,624
| -3% | -$978K | 0.04% | 365 |
|
|
2022
Q1 | $32.1M | Buy |
577,320
+34,036
| +6% | +$1.75M | 0.04% | 401 |
|
|
2021
Q4 | $30.4M | Sell |
543,284
-3,720
| -0.7% | -$202K | 0.04% | 391 |
|
|
2021
Q3 | $25.2M | Buy |
547,004
+16,224
| +3% | +$784K | 0.04% | 388 |
|
|
2021
Q2 | $22.2M | Sell |
530,780
-1,670
| -0.3% | -$64.7K | 0.03% | 434 |
|
|
2021
Q1 | $17.9M | Sell |
532,450
-395,520
| -43% | -$14.1M | 0.03% | 454 |
|
|
2020
Q4 | $32.4M | Sell |
927,970
-1,404,658
| -60% | -$48.6M | 0.05% | 331 |
|
|
2020
Q3 | $81M | Sell |
2,332,628
-382,560
| -14% | -$12.8M | 0.15% | 145 |
|
|
2020
Q2 | $88.9M | Sell |
2,715,188
-247,238
| -8% | -$7.89M | 0.18% | 123 |
|
|
2020
Q1 | $89.2M | Sell |
2,962,426
-84,254
| -3% | -$2.51M | 0.22% | 102 |
|
|
2019
Q4 | $88.2M | Buy |
3,046,680
+41,082
| +1% | +$1.14M | 0.17% | 126 |
|
|
2019
Q3 | $77.7M | Sell |
3,005,598
-914
| -0% | -$23.1K | 0.17% | 137 |
|
|
2019
Q2 | $76.7M | Buy |
3,006,512
+4,094
| +0.1% | +$101K | 0.17% | 133 |
|
|
2019
Q1 | $78.5M | Sell |
3,002,418
-20,952
| -0.7% | -$515K | 0.18% | 129 |
|
|
2018
Q4 | $69.6M | Sell |
3,023,370
-10,964
| -0.4% | -$244K | 0.18% | 131 |
|
|
2018
Q3 | $71.5M | Sell |
3,034,334
-11,058
| -0.4% | -$270K | 0.16% | 145 |
|
|
2018
Q2 | $70.2M | Buy |
3,045,392
+15,080
| +0.5% | +$358K | 0.17% | 142 |
|
|
2018
Q1 | $74.6M | Sell |
3,030,312
-12,722
| -0.4% | -$334K | 0.19% | 137 |
|
|
2017
Q4 | $81.7M | Sell |
3,043,034
-9,254
| -0.3% | -$235K | 0.2% | 128 |
|
|
2017
Q3 | $73.5M | Sell |
3,052,288
-17,050
| -0.6% | -$385K | 0.19% | 132 |
|
|
2017
Q2 | $65.8M | Sell |
3,069,338
-31,794
| -1% | -$642K | 0.17% | 136 |
|
|
2017
Q1 | $53.2M | Sell |
3,101,132
-34,038
| -1% | -$593K | 0.14% | 154 |
|
|
2016
Q4 | $56.2M | Sell |
3,135,170
-14,892
| -0.5% | -$270K | 0.16% | 149 |
|
|
2016
Q3 | $65.5M | Sell |
3,150,062
-50,364
| -2% | -$1.25M | 0.19% | 128 |
|
|
2016
Q2 | $86.1M | Sell |
3,200,426
-188,948
| -6% | -$5.18M | 0.25% | 107 |
|
|
2016
Q1 | $91.8M | Sell |
3,389,374
-102,610
| -3% | -$2.75M | 0.28% | 100 |
|
|
2015
Q4 | $101M | Sell |
3,491,984
-22,170
| -0.6% | -$614K | 0.3% | 91 |
|
|
2015
Q3 | $95.3M | Sell |
3,514,154
-7,420
| -0.2% | -$210K | 0.29% | 93 |
|
|
2015
Q2 | $96.4M | Sell |
3,521,574
-44,522
| -1% | -$1.25M | 0.29% | 96 |
|
|
2015
Q1 | $95.2M | Sell |
3,566,096
-11,138
| -0.3% | -$256K | 0.29% | 98 |
|
|
2014
Q4 | $75.7M | Sell |
3,577,234
-1,452
| -0% | -$32.4K | 0.22% | 112 |
|
|
2014
Q3 | $85.2M | Sell |
3,578,686
-11,294
| -0.3% | -$260K | 0.25% | 109 |
|
|
2014
Q2 | $82.9M | Sell |
3,589,980
-166,256
| -4% | -$3.67M | 0.25% | 112 |
|
|
2014
Q1 | $85.7M | Sell |
3,756,236
-271,444
| -7% | -$5.78M | 0.25% | 114 |
|
|
2013
Q4 | $74.4M | Sell |
4,027,680
-133,940
| -3% | -$2.33M | 0.21% | 120 |
|
|
2013
Q3 | $70.4M | Sell |
4,161,620
-15,740
| -0.4% | -$265K | 0.21% | 117 |
|
|
2013
Q2 | $64.7M | Buy |
+4,177,360
| New | +$69.5M | 0.2% | 118 |
|
Other funds holding NVO
F
Eaton Vance Management's NVO Position: Q3 2022 in Review
Eaton Vance Management increased its Novo Nordisk (NVO) stake by 289% in Q3 2022, buying an estimated $86.7M and bringing the position to 2,177,852 shares worth $108M. The position accounts for 0.16% of the portfolio, ranked #139.
Eaton Vance Management first reported a position in NVO in Q2 2013 and has held it in 38 quarters since. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.
- Eaton Vance Management held 2,177,852 shares of Novo Nordisk worth $108M as of Q3 2022.
- Eaton Vance Management bought 1,618,156 Novo Nordisk shares in Q3 2022, an estimated $86.7M.
- Novo Nordisk made up 0.16% of Eaton Vance Management's portfolio in Q3 2022, its #139 holding.
- Eaton Vance Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 38 quarters since.
- 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.